Staging, Pathology, and Risk Stratification: Understanding Your Profile

Your clinical lab results and your pathology report together form a roadmap that helps your doctor predict how the disease will behave and which treatments are most likely to work. This process is called risk stratification. By looking at three key markers—MIPI, Ki-67, and TP53—you and your care team can move away from a “one-size-fits-all” approach toward a highly personalized treatment plan.

1. The MIPI Score: Your Clinical Foundation

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a standard clinical tool used at the time of diagnosis to categorize patients into Low, Intermediate, or High-risk groups ^[1][2]. It is calculated using four specific variables:

• Age: Used because older age often affects how aggressively a patient can be treated.
• ECOG Performance Status: A 0-4 scale that measures your physical activity and ability to care for yourself.
• LDH (Lactate Dehydrogenase): A blood enzyme that increases when there is high cell turnover or tissue damage.
• White Blood Cell (WBC) Count: The number of white cells circulating in your blood.

While the MIPI score is a fundamental clinical tool, doctors combine it with biological markers from your biopsy to get a much more accurate picture ^[3][4].

2. Ki-67: The Speedometer

The Ki-67 proliferation index is a percentage found on your biopsy pathology report. It tells you how many of your cancer cells are actively dividing at any given moment. Think of it as a “speedometer” for your lymphoma.

• The 30% Threshold: Most doctors consider a Ki-67 score of 30% or higher to be a critical threshold ^[5][3]. Scores above this level indicate a more aggressive, faster-growing disease.
• MIPI-c: Many specialists now use the MIPI-c (combined) index, which merges your clinical MIPI score with your Ki-67 percentage. This combined score is significantly better at identifying which patients may need more intensive therapy ^[6][5].

3. TP53: The Most Critical Molecular Marker

The TP53 gene is responsible for repairing damaged DNA or “ordering” a highly damaged cell to die. If this gene is mutated—or if the piece of the chromosome that holds it is missing (called a 17p deletion)—the cancer cell loses this “self-destruct” button.

This is incredibly important because it means the lymphoma becomes much harder to treat with traditional, DNA-damaging chemotherapy ^[7][8].

For patients with a TP53 mutation, standard intensive chemotherapy and an autologous stem cell transplant (ASCT) are often ineffective and unnecessarily toxic ^[7][9]. Current guidelines emphasize that TP53 status must be checked before starting treatment ^[10]. If a mutation is present, this is actually empowering information: it allows your doctor to pivot away from a stem cell transplant and move directly to targeted therapies (like BTK inhibitors) or clinical trials, which offer better outcomes than traditional high-dose chemotherapy ^[7][11].

Auditing Your Report

You are encouraged to “audit” your own pathology and lab reports for these three markers. Having this data allows you to have a much more informed conversation with your oncologist about why a specific treatment is being recommended for your unique biological profile.

Read next about Standard of Care Treatment: The Frontline Approach.